Jeantet advises the China Medical System Group in connection with the acquisition of a participating interest in Eye Tech Care
Paris, 15 September 2022 – Jeantet has advised the Chinese group China Medical System in the context of (i) the acquisition of a participating interest, through certain subsidiaries of the group, of around 33.4% of the share capital of the French company Eye Tech Care and (ii) the signature of a license, collaboration and distribution agreement relating to the ultrasound glaucoma treatment device EyeOP1®.
Based in Shenzhen, the China Medical System group is a leader in the development and distribution of new medical treatments, particularly in the fields of dermatology and ophthalmology. This transaction aims to provide a new high-quality treatment option for glaucoma patients in China and Southeast Asian countries.
Founded in 2008 in Lyon by experts in therapeutic ultrasound and in partnership with INSERM, Eye Tech Care focuses on the application of therapeutic ultrasound technology in the fight against glaucoma, developing and promoting the EyeOP1® glaucoma treatment device for non-invasive UCP® treatment of this ophthalmological disease.
The Jeantet team was composed of Thierry Brun, (Partner), Maxime Brotz (Counsel), Pak-Hang Li, You Shang and Maria Plakci (Associates), for the Corporate/M&A aspects.
Eye Tech Care was advised by CMS Francis Lefebvre Avocats with Xinyu Hu and David Mantienne (Counsels), Yanchao Wu (Associate), for the Corporate/M&A aspects, Johann Roc’h and Henri Bitar (Partners) for the tax aspects, Nicolas Zhu (Partner – CMS Shanghai), and Laila Lu (Associate – CMS Shanghai), for the contract law aspects.